Nivolumab, a PD-L1 inhibitor, with or without the CTLA-4 inhibitor ipilimumab, proved ineffective in osteosarcoma, Ewing sarcoma, synovial sarcoma and DSRCT in the ADVL1412 trial. Here, CTLA4 is linked to osteosarcoma.